Potentia Pharmaceuticals, a speciality biotechnology company focused on treatments for AMD, have announced a licensing and share purchase option agreement with Alcon, Inc (ACL:NYSE). The… Read More »Potentia Pharmaceuticals licenses complement pathway inhibitor for macular degeneration
Researchers based at Duke University Medical Centre, North Carolina have developed a new technology using spectral domain optical coherence tomography (SD-OCT) to produce a three-dimensional… Read More »New handheld imaging device finds early signs of retinopathy in premature infants
Gene Signal [www.genesignal.com] based in Lausanne, Switzerland, have reported interim results of a randomized Phase II clinical study on their lead drug candidate, GS-101. The… Read More »Gene Signal’s GS-101 results show safe and effective inhibition of blood vessel growth
Roche / Genentech sign licensing and development deal to access drug delivery formulation for Lucent
SurModics of Minnesota announced the completion of a License and Development Agreement with Roche / Genentech Inc for the use of SurModics’ proprietary microparticulate drug… Read More »Roche / Genentech sign licensing and development deal to access drug delivery formulation for Lucent
Quark Pharmaceuticals, based in Freemont California, have announced preliminary results of a study using a chemically modified siRNA to down regulate a gene known as… Read More »Quark Pharmaceuticals presents results with siRNA for treatment of DMA and wet AMD
Paloma Pharmaceuticals have announced positive results with a small molecule inhibitor of the P13K/Akt/mTOR pathway implicated in a wide variety of biological responses.
Fovea Pharmaceuticals (Paris, France) and Dyax Corporation (Cambridge, Massachusetts, USA) have announced the execution of an exclusive license agreement for the development and commercialisation of… Read More »French and US companies combine efforts on retinal vein occlusion-induced macular edema